For Immediate Release
Chief Creative Officer
SHEPHERD THERAPEUTICS FOUNDER AND CEO DAVID HYSONG NAMED TO FORBES 30 UNDER 30: HEALTHCARE
Rare Cancer Patient Recognized for Contribution to Healthcare Sector
CAMBRIDGE, MA— January 3, 2017 — Today, SHEPHERD Founder and CEO David Hysong was announced as a member of the Forbes 30 Under 3o Class of 2017. As described on Forbes.com, the annual list seeks to honor “the brightest young entrepreneurs, breakout talents and change agents in 20 different sectors.” Mr. Hysong was selected for the Healthcare sector, joining an impressive class boasting a United Nations commissioner, postdoctoral fellows at the nation’s best medical schools, and several healthcare company founders.
Before being diagnosed with Adenoid Cystic Carcinoma—a rare and untreatable head-and-neck cancer—Mr. Hysong investigated the sexual enslavement of children in Cambodia, studied at Harvard Divinity School, and trained to join U.S. Military Special Operations. After learning about his own disease and meeting many rare cancer patients faced with a similar lack of therapies, Mr. Hysong founded SHEPHERD, a biotech company focused on finding treatments for rare cancers. In 2016, Mr. Hysong assembled a team of experts in the field and raised $6.5 million in angel investments.
“Thank you to Forbes and everyone who made this possible, especially the SHEPHERD team,” said Mr. Hysong. “I am humbled and incredibly energized to be chosen for the Forbes 30 Under 30 Class of 2017. SHEPHERD made great strides in 2016 and making the Forbes list is an encouraging affirmation of that. In 2017 I look forward to continue fighting for our mission of saving the life of every individual with rare cancer.”
About Forbes 30 Under 30
The list is an annual publication by Forbes magazine recognizing individuals under 30 years old for their contributions to one of 20 sectors. Forbes reporters carefully research nominees before the judges—field experts and 30 Under 30 alums—finally select a class of 30 individuals for each sector. This meticulous process yields a highly selective group: the acceptance rate for the 30 Under 30 Class of 2017 was <4%.
About SHEPHERD Therapeutics
The mission of SHEPHERD is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a biotechnology company relentlessly focused on using deep disease understanding, development expertise, and an unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.